Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines

Journal of Medical Virology

Volumn 78, Issue 2, 2006, Pages 169-177

  Zuckerman, Jane N ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

DNA vaccines; HBV mutants; Hepatitis B vaccines; Immune response; Immunotherapy; Safety

Indexed keywords

ANTIVIRUS AGENT; CY 1899; CYTOKINE; DNA VACCINE; EPITOPE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; INTERLEUKIN 2; LAMIVUDINE; LIPOPEPTIDE; MEASLES MUMPS RUBELLA VACCINE; PALMITIC ACID DERIVATIVE; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; T LYMPHOCYTE VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD TRANSFUSION; BODY MASS; CHRONIC FATIGUE SYNDROME; DEMYELINATING DISEASE; DENDRITIC CELL; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ENCEPHALOMYELITIS; GENDER; GENETIC MANIPULATION; HEALTH PROGRAM; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOTHERAPY; INJECTION SITE; MULTIPLE SCLEROSIS; NONHUMAN; ORGAN TRANSPLANTATION; RISK ASSESSMENT; SCREENING; SEROCONVERSION; SIDE EFFECT; SUDDEN INFANT DEATH SYNDROME; TH1 CELL; TH2 CELL; VACCINATION; VIRUS TRANSMISSION;

AGE FACTORS; ALLELES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HLA-DR ANTIGENS; HUMANS; INJECTIONS; MUTATION; SAFETY; SEX FACTORS; T-LYMPHOCYTES, HELPER-INDUCER; VACCINATION; VACCINES, DNA;

HEPATITIS B VIRUS;

EID: 31144471043     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20524     Document Type: Article

References (39)

1. Alper CA, Kruksall MS, Marcus_Bagley D, Craven DE, Katz AJ, Brink SJ, Dienstag JL, Awdeh Z, Yunis EJ. 1989. Genetic prediction of non-response to hepatitis B vaccine. New Eng J Med 321:708-712.
2. Arif M, Mitchison NA, Zuckerman AJ. 1988. Genetics of non-responders to hepatitis B surface antigen and possible ways of circumventing non-response. In: Zuckerman AJ, editor. Viral hepatitis and liver disease. New York: Alan R Liss. pp 714-716.
3. Ascherio A, Zhnag SM, Herbab MA, Olek MJ, Coplan PM, Brodovicz K, walker AM. 2001. Hepatitis B vaccination and the risk of multiple sclerosis. New Eng J Med 344:327-332.
4. Autram B, Carcelain G, Combadiere B, Debre P. 2004. Therapeutic vaccines for chronic infections. Science 305:205-208.
5. Banatvala JE, Boxall E, Heptonstall J, Zuckerman AJ. 1996. Immunisation strategies: Proposal drafted in London and reviewed in prevention of hepatitis B in the newborn, children and adolescents. London: Royal Coll Physicians, pp 1-113.
6. Beckebaum S, Cicinnati VR, Gerken G. 2002. DNA-based immunotherapy: Potential for the treatment of chronic viral hepatitis? Rev Med Virol 12:297-319.
7. Canada Communicable Disease Report. 1992. Adverse events following the administration of hepatitis B vaccines. Can Commun Dis Rep 18-7:49-53.
8. Canada Medical Association. 1993. Report of the working group on the possible relationship between hepatitis B vaccination and the chronic fatigue syndrome. Can Med Assoc J 149:314-316.
9. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC. 1990. Vaccine-induced escape mutant of hepatitis B virus. Lancet 336:325-329.
10. Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S. 2001. Vaccinations and the risk of relapse in multiple sclerosis. New Eng J Med 344:319-326.
11. Dahmen A, Herzog-Hauff S, Bocher WO, Galle PR, Lohr HF. 2002. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol 66:452-460.
12. European Consensus Group on Hepatitis B Immunity. 2002. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 355:561-565.
13. Francois G, Kew M, Van Damme P, Mphahled J, Meheus A. 2001. Mutant hepatitis B viruses: A matter of academic interest only or a problem with far-reaching implications? Vaccine 19:3799-3815.
14. Conclaves L, Albarrar B, Salmen S, Borges L, Fields H, Montes H, Soyano A, Diaz Y, Berruta L. 2004. The non-response to hepatitis B vaccination is associated with impaired lymphocyte activation. Virology 326:20-28.
15. Gout O, Lyon-Caen O. 1998. Sclerotic plaques and vaccination against hepatitis B. Rev Neurol (Paris) 154:205-207.
16. Heathcote J, McHutchinson J, Lee S, Tong M, Reener K, Minuk G, Wright T, Fikes J, Livingston B, Settle A, Chestnut R. 1999. A pilot study of the CY-T cell vaccine in subjects chronically infected with hepatitis B virus. The CY 1999 T Cell vaccine Study Group. Hepatology 30:531-536.
17. Hernan MA, Jick SS, Olek MJ, Jick H. 2004. Recombinant hepatitis B vaccine and the risk of multiple sclerosis. Neurology 63:838-842.
18. Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL. 1999. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 30:1312-1317.
19. Jarrosson L, Kolopp-Sarda MN, Aguillar P, Bene MC, Faure GC, Kohler C. 2004. Most humoral non-responders to hepatitis B vaccines develop HBV-specific cellular immune responses. Vaccine 22:3789-3796.
20. Jefferson T. 1998. Vaccination and its adverse effects: Real or perceived. Brit Med J 317:159-160.
21. Krusall MS, Alper CA, Awdeh Z, Yunis EJ, Marcus-Bagley D. 1992. The immune response to hepatitis B vaccine in humans: Inheritance patterns in families. J Exp Med 175:495-502.
22. Margolis HS. 1999. Testimony before the US house of representatives committee on government reform subcommittee on criminal justice, drug policy and human resources. www.cdc.gov/ncidod/diseases/hepatitis accessed May 26th 2005.
23. McDermott AB, Cohen SBA, Zuckerman JN, Madrigal J. 1999. Human leukocyte antigens influence the immune response to a pre-S1, pre-S2, S hepatitis B vaccine. Vaccine 17:330-339.
24. Michel M-L, Pol S, Brechot C, Tiollais P. 2001. Immunotherapy of chronic hepatitis B by anti-HBV vaccine: From present to future. Vaccine 19:2395-2399.
25. Milich DR, McLachlan A, Chisari FV, Kent SB, Thornton GB. 1986. Immune response to the pre-S1 region of hepatitis B surface antigen: A pre-S1-specific T cell response can bypass non-responsiveness to the pre-S2 and S regions of HbsAg. J Immunol 137:315-322.
26. Nainan OV, Stevens CE, Taylor PE, Margolis HS. 1997. Hepatitis B virus (HBV) mutants among mothers and infants and chronic hepatitis B infection. In: Rizzeto M, Purcell RH, Gerin GL, Verme G, editors. Viral Hepatitis and Liver Disease. Torino: Minerva Medica. pp 132-134.
27. Nainan OV, Khristova ML, Byun K, Xia G, Taylor PE, Stevens CE, Margolis HS. 2002. Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J Med Virol 68:319-327.
28. Oon C-J, Lim G-K, Zaho Y, Goh K-T, Tan K-L, Yo S-L, Hopes E, Harrison TJ, Zuckerman AJ. 1995. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine 13:699-702.
29. Oon C-J, Tan K-L, Harrison TJ, Zuckerman AJ. 1996. Natural history of hepatitis B surface antigen mutants in children. Lancet 348:1524.
30. Tourbah A, Gout O, Liblau R, Lyon-Caen O, Bougniot C, Iba-Zizen Cabanis EA. 1999. Encephalitis after hepatitis B vaccination: Recurrent disseminated encephalitis or MS? Neurology 53:396-401.
31. WER. 1999. Expanded Programme on Immunisation (EPI). Lack of evidence that hepatitis B vaccine causes multiple sclerosis. Wkly Epidemiol Rec 72:149-152.
32. Whittle H, Jaffar S, Warnsborough M, Mendy M, Dumpis U, Collinson A, Hall XX. 2002. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. Brit Med J 325:569-572.
33. Wilson JN, Nokes DJ, Carman WF. 1999. The predicted pattern of emergence of vaccine-resistant hepatitis B: A cause for concern? Vaccine 17:973-978.
34. Wraith DC, Goldman M, Lambert P-H. 2003. Vaccination and autoimmune disease: What is the evidence? Lancet 362:1659-1666.
35. Zuckerman JN. 1996. Non-response to hepatitis B vaccines and the kinetics of anti-HBs production. J Med Virol 50:283-288.
36. Zuckerman JN, Zuckerman AJ. 1998. Is there a need for boosters of hepatitis B vaccines? Viral Hepatitis Rev 4:43-46.
37. Zuckerman AJ, Zuckerman JN. 1999. Molecular epidemiology of hepatitis B virus mutants. J Med Virol 58:193-195.
38. Zuckerman JN, Zuckerman AJ. 2002. Recombinant hepatitis B triple antigen vaccine: Hepacare™. Expert Rev Vaccine 1:141-144.
39. Zuckerman JN, Cockcroft A, Zuckerman AJ. 1992. Site of injection for vaccination. Brit Med J 305:1158-1159.